MYH9 and hepatocellular carcinoma: Over the past several years, an increasing number of studies have shown that MYH9 is upregulated in many cancers, such as non-small cell lung cancer [10], colorectal cancer [11], prostate cancer [12], diffuse large B-cell lymphoma [13], renal cell carcinoma [14], glioma [15], and hepatocellular carcinoma [16].